Cilengitide trifluoroacetate

For research use only.

Catalog No.S7077 Synonyms: EMD 121974, NSC 707544

46 publications

Cilengitide trifluoroacetate Chemical Structure

CAS No. 199807-35-7

Cilengitide (EMD 121974, NSC 707544) is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 454 In stock
USD 270 In stock
USD 990 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Cilengitide trifluoroacetate has been cited by 46 publications

Purity & Quality Control

Choose Selective Integrin Inhibitors

Biological Activity

Description Cilengitide (EMD 121974, NSC 707544) is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.
Targets
αvβ3 receptor [1]
(Cell-free assay)
αvβ5 receptor [2]
(Cell-free assay)
4.1 nM 79 nM
In vitro

Cilengitide is a cyclized pentapeptide peptidomimetic designed to compete for the arginine-glycine-aspartic acid (RGD) peptide sequence that regulates integrin-ligand binding. Cilengitide selectively and potently blocks the ligation of theαvβ3 andαvβ5 integrins to provisional matrix proteins such as vitronectin, fibronectin, fibrinogen, von Willebrand factor, osteopontin, and others. [1] Cilegitide inhibits angiogenesis in vitro. 10 μM Cilengitide completely inhibits attachment of BAE, BME and HUVE cells on vitronectin and fibronectin. Cilengitide inhibits in vitro angiogenesis of BAE cells on three-dimensional collagen and fibrin gels pretreated with FGF-2(or VEGF-A) with IC50 of 15 μM and 8 μM, 4 μM and 3 μM, respectively. [2] Cilengitide blocks proliferation and induces apoptosis of endothelial cells as well as differentiation of human endothelial precursor cells (EPCs). 50 μg/mL Cilengitide completely inhibits the proliferation of human microvascular endothelial cell line HMEC-1 and leads to apoptosis in ~30% cells. [3] 1.0 μM Cilengitide treating for 9 days inhibits the proliferation of EPCs by nearly 40%. 1 μM Cilengitide inhibits the differentiation of EPCs by more than 80% at 14 days. [4] Cilengitide inhibits adhesion and induces apoptosis of tumor cells. 25 μg/mL Cilengitide causes detachment of DAOY cells (medulloblastoma) and U87MG cells (glioblastoma) from vitronectin and tenascin by more than 60%. 25 μg/mL Cilengitide induces a nearly 50% apoptosis rate of these cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
G28 NX3PdXdPTnWwY4Tpc44hSXO|YYm= Mn[xOVAh|rypL33s MX:zNE83OC9zMkCgcYlv NGj2cIFqdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YhTkGNLDDTdoMh[W6mIFHreC=> MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTFzNECwOUc,OTlzMUSwNFU9N2F-
HMEC-1  M4XmeGZ2dmO2aX;uJGF{e2G7 MmiwNlAwPDBxNkCg{txoN22u MkTJbY5pcWKrdIOgSmFMKGGwZDDTdoPDqA>? NYrFW29RRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNVQxODVpPkG5NVE1ODB3PD;hQi=>
G44 NUThRVlRSXCxcITvd4l{KEG|c3H5 M3HselEwPS93MDFOwIcwdWx? M3rUPVI1KGh? NWPUfY9FcW6mdXPld{BieG:ydH;zbZM> MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTFzNECwOUc,OTlzMUSwNFU9N2F-
G28 NVzIVIhESXCxcITvd4l{KEG|c3H5 NFXEO4kyNzVxNUCg{txoN22u NUHCVFRIOjRiaB?= MnzKbY5lfWOnczDhdI9xfG:|aYO= NY\xTFdrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNVQxODVpPkG5NVE1ODB3PD;hQi=>
G44 MXzQdo9tcW[ncnH0bY9vKEG|c3H5 M1zh[VEwPS93MDFOwIcwdWx? NV25ZXQ5OjRxNEivO|IhcA>? NEXMRpNqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NHPGTFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGxOFAxPSd-MUmxNVQxODV:L3G+
G28 NITH[WRRem:uaX\ldoF1cW:wIFHzd4F6 NGroR3oyNzVxNUCg{txoN22u NYe4OphROjRxNEivO|IhcA>? M2PTbYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NGK4SZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGxOFAxPSd-MUmxNVQxODV:L3G+
HMEC-1  NHPORWVCeG:ydH;zbZMhSXO|YYm= NHfTS2gyNzVxNUCg{txoN22u NYTmOodFOjRiaB?= M3HKU4lv\HWlZYOgZZBweHSxc3nz NGT3e4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGxOFAxPSd-MUmxNVQxODV:L3G+
HMEC-1  MV3Qdo9tcW[ncnH0bY9vKEG|c3H5 NH\LXFAyNzVxNUCg{txoN22u MorVNlQwPDhxN{KgbC=> MWPpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz M1fOPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUG0NFA2Lz5zOUGxOFAxPTxxYU6=
HMEC-1  MYjGeY5kfGmxbjDBd5NigQ>? M33KT|EwPS93MDFOwIcwdWx? MmTqNlQhcA>? MkG4bY5lfWOnczDhJIRwe2ViZHXw[Y5l\W62IHTleIFkcG2nboVCpC=> MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTFzNECwOUc,OTlzMUSwNFU9N2F-
LNT-229  NETpfVVHfW6ldHnvckBCe3OjeR?= NYW3TJJCOC5zL{GvNVAh|ryP NXrlVGJROjRiaB?= NFuybJFqdXCjaYLzJJRp\SCjZHjld4lwdiCxZjDj[YxteyC2bzD2bZRzd26nY4TpckBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MoHKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{MkGxO|EoRjF7MkKxNVcyRC:jPh?=
T98G M16yNmZ2dmO2aX;uJGF{e2G7 MorENE4yNzFxMUCg{txO MVOyOEBp NUnnfXpLcW2yYXnyd{B1cGViYXTo[ZNqd25ib3[gZ4VtdHNidH:geol1em:wZXP0bY4hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MmD5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{MkGxO|EoRjF7MkKxNVcyRC:jPh?=
LN-18 MX\GeY5kfGmxbjDBd5NigQ>? NGPHPGwxNjFxMT:xNEDPxE1? M33KTFI1KGh? MkD6bY1x[Wm{czD0bIUh[WSqZYPpc44hd2ZiY3XscJMhfG9idnn0do9v\WO2aX6gbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= Ml7QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{MkGxO|EoRjF7MkKxNVcyRC:jPh?=
LN-308 NGG1dnZHfW6ldHnvckBCe3OjeR?= MnrWNE4yNzFxMUCg{txO M1XtTFI1KGh? MnW1bY1x[Wm{czD0bIUh[WSqZYPpc44hd2ZiY3XscJMhfG9idnn0do9v\WO2aX6gbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NEPRZXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUKyNVE4OSd-MUmyNlEyPzF:L3G+
U87MG MWDGeY5kfGmxbjDBd5NigQ>? NXLlWnB3OC5zL{GvNVAh|ryP NYDjcpRxOjRiaB?= MoXFbY1x[Wm{czD0bIUh[WSqZYPpc44hd2ZiY3XscJMhfG9idnn0do9v\WO2aX6gbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= M3jRTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkKxNVcyLz5zOUKyNVE4OTxxYU6=
U87  NILlW45HfW6ldHnvckBCe3OjeR?= NUjQS5Z5OC1{NTFOwIcwdUx? MVOxNkBpyqB? MV\pcoR2[2W|IHH1eI9xcGGpeTDkc5NmKGSncHXu[IVvfGy7 MkTBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5OEizOFMoRjJzN{i4N|Q{RC:jPh?=
U251 MlHHSpVv[3Srb36gRZN{[Xl? M3:4WlAuOjVizsznM41N M3LKN|EzKGkEoB?= M2nMfYlv\HWlZYOgZZV1d3CqYXf5JIRwe2ViZHXw[Y5l\W62bIm= M{C3dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{i4N|Q{Lz5{MUe4PFM1OzxxYU6=
U87  NEHmZVRCeG:ydH;zbZMhSXO|YYm= NXrXNXBkOjVizsznM41N MYqyOE81QCCq M2XyWYlv\HWlZYOgZZBweHSxc3nzJIF1KDR6IHigd4lodmmoaXPhcpRtgQ>? Mk\CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5OEizOFMoRjJzN{i4N|Q{RC:jPh?=
U251 MYfBdI9xfG:|aYOgRZN{[Xl? M3jZR|I2KM7:Zz;tUC=> Mk[wNlQwPDhiaB?= M4\RSYlv\HWlZYOgZZBweHSxc3nzJIF1KDR6IHigd4lodmmoaXPhcpRtgQ>? NFz6NnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe4PFM1Oyd-MkG3PFg{PDN:L3G+
U87  NXL1[Y1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XTU|AuOjVizsznM41N Ml6wNE01QCCq MYrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= M4f4VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{i4N|Q{Lz5{MUe4PFM1OzxxYU6=
U251 NVPSeFF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvCNE0zPSEQvHevcWw> NV;Xd5k{OC12ODDo NV33OJMzcW6qaXLpeJMh[2WubDDndo94fGhiaX6g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd6OEO0N{c,OjF5OEizOFM9N2F-
U251MG MVTBdI9xfG:|aYOgRZN{[Xl? NF3uRYwyKML3TR?= NFHJXW81QCCq NGjXTVlqdmS3Y3XzJIFxd3C2b4Ppdy=> MkHJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|NUS4NFcoRjJ|M{W0PFA4RC:jPh?=
U87MG MVnBdI9xfG:|aYOgRZN{[Xl? NGPlXZMyKML3TR?= NHX3VIQ1QCCq NVqwbppycW6mdXPld{BieG:ydH;zbZM> NEPs[pg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O1OFgxPyd-MkOzOVQ5ODd:L3G+
U251MG NV7y[pZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTyNE0zPSEQvF2= M4jLcVI1NzR6IHi= MnXnbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy Mlm5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|NUS4NFcoRjJ|M{W0PFA4RC:jPh?=
U87MG MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUCwXJF5OC1{NTFOwG0> NWHjPGJFOjRxNEigbC=> MV;pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= M3\WPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{W0PFA4Lz5{M{O1OFgxPzxxYU6=
MCF-7  MXPBdI9xfG:|aYOgRZN{[Xl? M3jFN|AuOjBizszN M3\VV|Q5KGh? MknQbY5lfWOnczDhdI9xfG:|aYO= MmXHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNUOxNFIoRjJ2MUWzNVAzRC:jPh?=
T-47D NEPGWIVCeG:ydH;zbZMhSXO|YYm= MWKwMVIxKM7:TR?= NFrOeWg1QCCq NGm0TVZqdmS3Y3XzJIFxd3C2b4Ppdy=> NVnQb3ZjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOVMyODJpPkK0NVU{OTB{PD;hQi=>
MCF-7  NYXFU3dsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTrNE0zOCEQvF2= NUHkOGl2QTZiaB?= NUn6[2s5cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NVvKOY5ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOVMyODJpPkK0NVU{OTB{PD;hQi=>
T-47D MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV6wMVIxKM7:TR?= MnryPVYhcA>? NIP4dmFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M1PRO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUWzNVAzLz5{NEG1N|ExOjxxYU6=
FaDu  MX\BdI9xfG:|aYOgRZN{[Xl? NFHqTVczPcLiwsXNxsA> MW[0POKhcMLi NGT4UmNqdmS3Y3XzJIFxd3C2b4Ppdy=> NWrie|B[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OVcxPTZpPkK0OVU4ODV4PD;hQi=>
CAL27 MX\BdI9xfG:|aYOgRZN{[Xl? MljtNlXDqML3TdMg MX60POKhcMLi MX7pcoR2[2W|IHHwc5B1d3Orcx?= NXLOS4RXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OVcxPTZpPkK0OVU4ODV4PD;hQi=>
SCC25 M175XGFxd3C2b4Ppd{BCe3OjeR?= MYeyOeKhyrWPwrC= MUO0POKhcMLi Mln2bY5lfWOnczDhdI9xfG:|aYO= NFnsPFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW1O|A2Pid-MkS1OVcxPTZ:L3G+
FaDu  NFjScHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV[2MlI26oDVMkCwxsDDvU1? M3;W[VczKGh? NG\yRXVz\XO3bITzJI1w\GW{YYTlMEBld3OnLXTldIVv\GWwdDDndo94fGhiaX7obYJqfGmxbh?= MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV3N{C1Okc,OjR3NUewOVY9N2F-
CAL27 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPx[XYxPi5{NfMAl|IxOMLiwsXN MlnhO|IhcA>? NYr3WIpCemW|dXz0d{Bud2SncnH0[Uwh\G:|ZT3k[ZBmdmSnboSg[5Jwf3SqIHnubIljcXSrb36= MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV3N{C1Okc,OjR3NUewOVY9N2F-
SCC25 NEPMUVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXoXGo3NjJ34pETNlAxyqEEtV2= M4TNfFczKGh? MmTYdoV{fWy2czDtc4RmemG2ZTyg[I9{\S2mZYDlcoRmdnRiZ4Lve5RpKGmwaHnibZRqd25? NF20Tmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW1O|A2Pid-MkS1OVcxPTZ:L3G+
H28 M2HBXGNmdGxiVnnhZoltcXS7IFHzd4F6 M33QRVEhdk1vMkCwJO69VQ>? NIO0THY4OiCq NWnaR4t5\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NVq2O3dtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1PVUzPzRpPkK0OVk2Ojd2PD;hQi=>
MM05 MnPHR4VtdCCYaXHibYxqfHliQYPzZZk> NHLs[JEyKG6PLUKwNEDPxE1? M1zQeFczKGh? NYrNPFlZ\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy Ml3sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3OUWyO|QoRjJ2NUm1Nlc1RC:jPh?=
MSTO-211H MXHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3HndlEhdk1vMkCwJO69VQ>? NIDxNZc4OiCq M{K5bYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MmXvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3OUWyO|QoRjJ2NUm1Nlc1RC:jPh?=
REN NEXWO3lE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Mn6xNUBvVS1{MECg{txO NHvnXpo4OiCq Ml3G[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M4jVe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUm1Nlc1Lz5{NEW5OVI4PDxxYU6=
LN-308  NU\ORYRQTnWwY4Tpc44hSXO|YYm= MVixNQKBkc7:bR?= M4PqcFI1KGh? M1\lSWROW00EoB?= MnLpdoVlfWOnczDBbHIheHKxdHXpckBt\X[nbIOgZY5lKESURTDy[ZBwenSncjDhZ5Rqfmm2eR?= MlzBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3MECwOVYoRjJ4NUCwNFU3RC:jPh?=
HaCaT  NX71Z4l[TnWwY4Tpc44hSXO|YYm= NHy4bVYyOOLCid88cS=> NG[zOow1QCCq MWDEUXNQyqB? M{KxTZJm\HWlZYOgWGdHNc7{MtMgcXJPSSCneIDy[ZN{cW:w NFrBc249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkWwNFA2Pid-Mk[1NFAxPTZ:L3G+
S-24 NWraS2pwTnWwY4Tpc44hSXO|YYm= MVuxM|Ex6oDLzszt MXuyOEBp NEP5U25FVVORwrC= MYHy[YR2[2W|IFTSSUBz\XCxcoTldkBi[3Srdnn0fS=> MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjVyMEC1Okc,OjZ3MECwOVY9N2F-
ZH-161 M4PnU2Z2dmO2aX;uJGF{e2G7 MVKxM|Ex6oDLzszt MmOxNlQhcA>? MUTEUXNQyqB? NEfBU29z\WS3Y3XzJGRTTSC{ZYDvdpRmeiCjY4Tpeol1gQ>? MnTYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3MECwOVYoRjJ4NUCwNFU3RC:jPh?=
LN-308  MX7GeY5kfGmxbjDBd5NigQ>? NF;jZXEyNzFyL{GwNQKBkc7:bR?= MXWyOEBp Mn:2SG1UV8Li Mn7WdoVlfWOnczDEVmUhemWyb4L0[ZIh[WO2aY\peJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> MnvLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3MECwOVYoRjJ4NUCwNFU3RC:jPh?=
M21 MoLlSpVv[3Srb36gZZN{[Xl? MXmxJIhz MorsRolv\GmwZzDh[oZqdmm2eTD0c{BqdnSnZ4LpckBidHCqYY[vZoV1[TNiaHX0[ZJw\GmvZYKgbY4hcHWvYX6gUVIyKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gbY51\We{aX6tcYVlcWG2ZXSgbJVu[W5iTUKxJINmdGxiYXTo[ZNqd25idH:geol1em:wZXP0bY4h[W[2ZYKgNUBpeiCrbjDwdoV{\W6lZTDv[kBOdkOuMjygTWM2OCB;IECuNFAxPCEQvF2u MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd3M{ixOEc,OjZ5NUO4NVQ9N2F-
HEK293T NXO5ZZhmTnWwY4Tpc44h[XO|YYm= NVfqenVPOiCqcoO= M1T0UmJqdmSrbnegZYZncW6rdImgeI8he2:udXLs[UB1enWwY3H0[YQhcHWvYX6gdoVkd22kaX7hcpQhTmNvdHHn[4VlKGGucHjhWoJmfGF|IHHu[EBqdnSnZ4LpcpMhf2W{ZTDlfJBz\XO|ZXSgbY4hUEWNMkmzWEBk\WyuczDh[pRmeiB{IHjyd{BjgSClb33w[ZRqfGmxbjDFUGlUSS2uaXvlJIF{e2G7LDDJR|UxKD1iMD6wNFA2OSEQvF2u NVvGR5ZRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVUxQTZpPkK0NFk2ODl4PD;hQi=>
HT-29 M3XZe2Z2dmO2aX;uJIF{e2G7 NE\YOo0zKGi{cx?= MVrBcpRi\2:waYP0JIFkfGm4aYT5JIF1KGmwdHXndolvKGGucHjhWoJmfGF3IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJGhVNTJ7IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBk\WyuIHHkbIV{cW:wIITvJJZqfHKxbnXjeIlvKGGodHXyJFIhcHK|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvOTJizszNMi=> NXrBb|R6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizOVE2QTRpPkK4N|UyPTl2PD;hQi=>
HEK293 NHvVW4ZHfW6ldHnvckBie3OjeR?= MoOwNkBpenN? M{fuO2FvfGGpb37pd5Qh[WO2aY\peJkh[XRiaX70[YdzcW5iYXzwbIFX[mW2YUOgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJIFlcGW|aX;uJJRwKG[rYoLpco9o\W5iYX\0[ZIhOiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5{MjFOwG0v NUXKPXdzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizOVE2QTRpPkK4N|UyPTl2PD;hQi=>
SKOV3 MlrrSpVv[3Srb36gZZN{[Xl? MWOyJIhzew>? NIrmcolCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IHnueIVoemmwIHHsdIhiXmKndHGzZYxxcGGYYnX0ZVUhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iU1vPWlMh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwh[WSqZYPpc44hfG9iZnnidolvd2enbjDh[pRmeiB{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkO3JO69VS5? MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN3MUW5OEc,Ojh|NUG1PVQ9N2F-
U87MG MVrGeY5kfGmxbjDhd5NigQ>? MUCxNFAhdk1? NGPLOI4zPCCqcoO= M{L4NGlvcGmkaYTpc44hd2ZiYXzwbIFX[mW2YUOgbY51\We{aX6gbY4hcHWvYX6gWVg4VUdiY3XscJMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gdFU{KGGlY4XteYxifGmxbjDheEAyODBibl2gZYZ1\XJiMkSgbJJ{KGK7IGfld5Rmem5iYnzveEBu\XSqb3S= M3rJRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{e1N|A{Lz5{OUe3OVMxOzxxYU6=
U87MG NFjqOJdHfW6ldHnvckBie3OjeR?= MYqxNFAhdk1? MXiyOEBpenN? NXP6SWlyUW6qaXLpeIlwdiCxZjDhcJBp[V[kZYThN{BqdnSnZ4LpckBqdiCqdX3hckBWQDePRzDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBxPTNiYXPjeY12dGG2aX;uJIF1KDFyMDDuUUBi\nSncjCyOEBpenNiaX6gdJJme2WwY3Wgc4YhVUSPMjDpcohq[mm2b4KgcpV1dGmwLUOgZpkhX2W|dHXyckBjdG:2IH3leIhw\A>? M1TLclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{e1N|A{Lz5{OUe3OVMxOzxxYU6=
U87MG NXHFfol[TnWwY4Tpc44h[XO|YYm= M3vP[VExOCCwTR?= M3LISlI1KGi{cx?= NHex[XRKdmirYnn0bY9vKG:oIHHsdIhiXmKndHGzJIlvfGWpcnnuJIlvKGi3bXHuJHU5P02JIHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJJA2OyCjY3P1cZVt[XSrb36gZZQhOTByIH7NJIFnfGW{IEK0JIhzeyCrbjDwdoV{\W6lZTDv[kBOTE1{IHnubIljcXSxcjDueZRtcW5vMzDhcoQhVUSPNDDpcohq[mm2b4KgV2ouOTd{MkW1NEBjgSCZZYP0[ZJvKGKub4SgcYV1cG:m MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd5NUOwN{c,Ojl5N{WzNFM9N2F-
U87MG M33OWWZ2dmO2aX;uJIF{e2G7 NVnIPJFSOTByIH7N MYK4JIhzew>? NH\MTIZKdmirYnn0bY9vKG:oIHHsdIhiXmKndHGzJIlvfGWpcnnuJIlvKGi3bXHuJHU5P02JIHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJG1FVTJibWLORUBmgHC{ZYPzbY9vKGG2IEGwNEBvVSCjZoTldkA5KGi{czDpckBxemW|ZX7j[UBw\iCPRF2yJIlvcGmkaYTvdkBvfXSuaX6tN{BidmRiTVTNOEBqdmirYnn0c5IhW0pvMUeyNlU2OCCkeTDSWE1RS1JibXX0bI9l NHLieXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe3OVMxOyd-Mkm3O|U{ODN:L3G+
U87MG MoLqSpVv[3Srb36gZZN{[Xl? M1zCWFExOCCwTR?= NGq1R2IzPCCqcoO= M1HEdWlvcGmkaYTpc44hd2ZiYXzwbIFX[mW2YUOgbY51\We{aX6gbY4hcHWvYX6gWVg4VUdiY3XscJMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gVHVOSSCvUl7BJIV5eHKnc4Ppc44h[XRiMUCwJI5OKGGodHXyJFI1KGi{czDifUBTXC2SQ2KgcYV1cG:m M37UUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{e1N|A{Lz5{OUe3OVMxOzxxYU6=
U87MG NXXnUWFtTnWwY4Tpc44h[XO|YYm= NWHDfnkxOTByIH7N NHjMbpMzPCCqcoO= MorKTY5pcWKrdHnvckBw\iCjbIDoZXZj\XSjMzDpcpRm\3KrbjDpckBpfW2jbjDVPFdOTyClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDQWW1CKG2UTlGg[ZhxemW|c3nvckBifCBzMECgcm0h[W[2ZYKgNlQhcHK|IHnuJJBz\XOnbnPlJI9nKE2GTUKgbY5pcWKrdH;yJI52fGyrbj2zJIJ6KFKWLWDDVkBu\XSqb3S= M{jWeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{e1N|A{Lz5{OUe3OVMxOzxxYU6=
U87MG M4OycGZ2dmO2aX;uJIF{e2G7 MWexNFAhdk1? MkjLNlQhcHK| MWDJcohq[mm2aX;uJI9nKGGucHjhWoJmfGF|IHnueIVoemmwIHnuJIh2dWGwIGW4O21IKGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIGDVUWEhdVKQQTDlfJBz\XO|aX;uJIF1KDFyMDDuUUBi\nSncjCyOEBpenNiaX6gdJJme2WwY3Wgc4YhVUSPNDDpcohq[mm2b4KgV2ouOTd{MkW1NEBjgSCUVD3QR3IhdWW2aH;k MlLQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5N{WzNFMoRjJ7N{e1N|A{RC:jPh?=
U87MG MlnSSpVv[3Srb36gZZN{[Xl? NX3NWI5oOTByIH7N M{XIR|I1KGi{cx?= NV;Qe3VDUW6qaXLpeIlwdiCxZjDhcJBp[V[kZYThN{BqdnSnZ4LpckBqdiCqdX3hckBWQDePRzDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBRXU2DIH3SUmEh\XiycnXzd4lwdiCjdDCxNFAhdk1iYX\0[ZIhOjRiaILzJIlvKHC{ZYPlcoNmKG:oIF3EUVIhcW6qaXLpeI9zKG63dHzpck0{KGGwZDDNSG01KGmwaHnibZRweiCVSj2xO|IzPTVyIHL5JHJVNVCFUjDt[ZRpd2R? MnvxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5N{WzNFMoRjJ7N{e1N|A{RC:jPh?=
U87MG M3PQVGZ2dmO2aX;uJIF{e2G7 M4nkTlExOCCwTR?= NITyWFMzPCCqcoO= NGPWXJdKdmirYnn0bY9vKG:oIHHsdIhiXmKndHGzJIlvfGWpcnnuJIlvKGi3bXHuJHU5P02JIHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJJAzOSCvUl7BJIV5eHKnc4Ppc44h[XRiMUCwJI5OKGGodHXyJFI1KGi{czDifUBTXC2SQ2KgcYV1cG:m MmrlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5N{WzNFMoRjJ7N{e1N|A{RC:jPh?=
U87MG M4OwU2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 MVexNFAhdk1? NGDPe|Y4OiCqcoO= NWPUeYpsSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVPFdOTyClZXzsd{BifCBzMECgcm0h[W[2ZYKgO|IhcHK|IHnuJJBz\XOnbnPlJI9nKE2GTUKgbY5pcWKrdH;yJI52fGyrbj2zJIJ6KE2WUzDhd5NigQ>? NVvXPGR2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O|U{ODNpPkK5O|c2OzB|PD;hQi=>
U87MG M4\hSmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 Mn3VNVAxKG6P Mk\6O|IhcHK| NWDHbIZFSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVPFdOTyClZXzsd{BifCBzMECgcm0h[W[2ZYKgO|IhcHK|IHnuJJBz\XOnbnPlJI9nKE2GTUKgbY5pcWKrdH;yJI52fGyrbj2zJIFv\CCPRF20JIlvcGmkaYTvdkBUUi1zN{KyOVUxKGK7IF3UV{Bie3OjeR?= NIPRZ5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe3OVMxOyd-Mkm3O|U{ODN:L3G+
U87MG MVfD[YxtKGO7Y3zlJIF{e2G7 NFW3WXMyODBibl2= NXXrWZhtOjRiaILz M4HMV2NmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJHU5P02JIHPlcIx{KGG|c3Xzd4VlKGG|IHHjZ5VufWyjdHnvckBifCCJMD;HNUBxcGG|ZTDheEAyODBibl2gZYZ1\XJiMkSgbJJ{ NFXq[oc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe3OVMxOyd-Mkm3O|U{ODN:L3G+
U87MG M2r2b2FvfGlvaX72ZZNqfmViYYPzZZk> MXexNEB2VQ>? MknTNlQhcHK| MoG3RY51cS2rbo\hd4l3\SCjY4Tpeol1gSCrbjDoeY1idiCXOEfNS{Bk\WyuczDheEAyOCC3TTDh[pRmeiB{NDDodpMh[nlidILhcpN4\WyuIHHzd4F6 Mlj4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5N{WzNFMoRjJ7N{e1N|A{RC:jPh?=
U87MG MlfBRY51cS2rbo\hd4l3\SCjc4PhfS=> NXTZemZFOTBidV2= MlPpNlQhcHK| MVPBcpRqNWmwdnHzbZZmKGGldHn2bZR6KGmwIHj1cYFvKFV6N13HJINmdGy|IHH0JFExKHWPIHHmeIVzKDJ2IHjyd{BqdiCycnXz[Y5k\SCxZjDNSG0zKGmwaHnibZRweiCwdYTsbY4uOyCjbnSgUWROPCCrbnjpZol1d3JiU1qtNVczOjV3MDDifUB1emGwc4flcIwh[XO|YYm= MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd5NUOwN{c,Ojl5N{WzNFM9N2F-

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pFAK / p-AKT ; 

PubMed: 19114005     


G28 cells were treated with 50 μg/ml cilengitide for 30, 60 and 120 minutes at 37°C. Cell lysates containing similar amounts of protein were separated by SDS-PAGE, transferred to a nitrocellulose membrane and probed with specific antibodies for detection of β-actin and phosphorylated FAK and Akt.

GLI1; 

PubMed: 31366904     


Western blottingting showing downregulated GLI1 with Integrin αvβ3 inhibitor Cilengitide and upregulated GLI1 with co-stimulator ligand RGD compared to the blank control in SGC7901 MCAs and BGC823 MCAs. 

19114005 31366904
Immunofluorescence
VE-cadherin / β3 integrin ; 

PubMed: 19212436     


Confluent HUVEC plated on fibronectin or collagen I were exposed to cilengitide (10 µM each) for the indicated time and double stained for VE-cadherin and β3 integrin. Cilengitide disrupted VE-cadherin staining and promoted appearance of β3 at VE-cadherin-depleted cell-cell borders. Higher magnification of HUVEC cultures demonstrate rare co-localization of VE-cadherin and β3 integrin at cellular junctions upon cilengitide stimulation (arrowheads). Bars: 10 µm.

19212436
Growth inhibition assay
Cell number ; 

PubMed: 24153102     


Cell detachment following 1 hr Cilengitide treatment. Cells were treated with cilengitide for 1 hr, washed with PBS, and remaining attached cells were trypsinized and counted. A) T-47D cells showed a strong dose response, with almost complete cell detachment at 20 uM cilengitide treatment. B) MCF-7 cells showed moderate cell detachment similar to C) MDA-MB-231 cells. D) MDA-MB-468 cells showed little to no cell detachment following this short exposure to cilengitide. Figures show Mean ± SEM and represent the average of three experiments. * = ≤ 0.05.

24153102
In vivo Cilengitide is activity against tumor growth and angiogenesis as single-agent. 100 μg Cilengitide induces a significant decrease in the number of CD 31+ vessels seen in tumors (2/high-power field) compared with control tumors (56/high-power field). 100 μg Cilengitide increases cellular apoptosis in the brain tumors of animals (2.2% apoptotic cells/high-power field) compared with those receiving the inactive peptide (1.7% cells/high-power field). Cilengitide treatment results in prolonged survival of the mice bearing melanoma xenografts M21 compared with control treatment group. (36.5 vs 17.3 days). [5] Cilengitide can augment the therapeutic benefit associated with cytotoxic agents including chemotherapy and radiation therapy in tumor models. Cilengitide (250 mg/dose) alone does not alter tumor growth of breast cancer xenografts when compared with untreated mice, but combined modality RIT (CMRIT) using RIT and six doses of Cilengitide (250 mg/dose) increases efficacy of treatment, with the cure rate for mice that receives only RIT increasing from 15 to 53%. CMRIT significantly increases apoptosis of tumor and endothelial cells 5 days, and decreases tumor proliferation. [6]

Protocol

Kinase Assay:[2]
- Collapse

Integrin-binding competition assay:

Recombinant soluble integrins are immobilized, and peptides, which are serially diluted in Tris-buffered saline (TBS++) (0.1% (w/v) BSA, 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2 10 μM MnCl2, 20 mM Tris-HCl; pH 7.4), are added in parallel with biotinylated vitronectin (to 1μg/mL). After a 3-h incubation at 37℃ and washing with Tris–buffered saline, bound ligand is detected by incubation with an antibiotin alkaline phosphatase-conjugated antibody (BioRad) followed by development with p-nitrophenyl phosphatase substrate. The reaction is stopped by the addition of NaOH and the color intensity read at 405 nm.
Cell Research:[3]
- Collapse
  • Cell lines: Human microvascular endothelial cell line HMEC-1
  • Concentrations: 1-50 μg/mL
  • Incubation Time: 3 days
  • Method: HMEC-1 (1×104 per well) are seeded on uncoated 48 well plates and incubated in medium containing 4% FCS with Cilengitide. After incubation for 72 hours at 37℃, cells are trypsinized and counted.
    (Only for Reference)
Animal Research:[5]
- Collapse
  • Animal Models: Human glioblastoma xenografts U87 MG
  • Dosages: 100μg
  • Administration: Daily i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (142.31 mM)
Water 8 mg/mL (11.38 mM)
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 702.68
Formula

C29H41F3N8O9

CAS No. 199807-35-7
Storage powder
in solvent
Synonyms EMD 121974, NSC 707544
Smiles CC(C)C1C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N1C)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N.C(=O)(C(F)(F)F)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01517776 Terminated Drug: Cilengitide|Drug: Temozolomide Gliomas Martin-Luther-Universität Halle-Wittenberg|Merck KGaA Darmstadt Germany January 2012 Phase 2
NCT01118676 Completed Drug: cilengitide radiochemotherapy Locally Advanced Non Small Cell Lung Cancer (NSCLC)* Institut Claudius Regaud|Merck KGaA Darmstadt Germany March 2010 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    The recommend vehicle is 30% propylene glycol, 5% Tween 80, 65% D5W at 30mg/ml, can you let me know if this is a suspension or clear solution?

  • Answer:

    S7077 Cilengitide can be dissolved in 30% propylene glycol/5% Tween 80/65% D5W at 10 mg/ml as a clear solution.

  • Question 2:

    Is Cilengitide a TFA salt?

  • Answer:

    S7077 Cilengitide is actually a TFA salt, and the ratio between Cilengitide and TFA is 1:1.

Integrin Signaling Pathway Map

Tags: buy Cilengitide trifluoroacetate | Cilengitide trifluoroacetate supplier | purchase Cilengitide trifluoroacetate | Cilengitide trifluoroacetate cost | Cilengitide trifluoroacetate manufacturer | order Cilengitide trifluoroacetate | Cilengitide trifluoroacetate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID